

N064B, Randomized Phase II Trial of Panitumumab, Erlotinib, and Gemcitabine vs. Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma

Status Change – December 30, 2009

The safety analysis portion of this study to determine dose limiting toxicities (DLT) and maximum tolerated dose (MTD) has been completed. Per protocol design, the study will now re-open to the randomization phase effective December 30, 2009 and patients will be randomized to either Arm A or Arm B. Patient may be enrolled through remote registration.

Patients will be treated at Dose Level -1 as follows:

Gemcitabine: 1000 mg/ m²

Panitumumab: 4.0 mg/kg

Erlotinib: 100 mg

An addendum to the protocol will follow.

Please retain this notice with the protocol.